2. 筋萎縮性側索硬化症 Amyotrophic lateral sclerosis Clinical trials / Disease details
臨床試験数 : 645 / 薬物数 : 589 - (DrugBank : 163) / 標的遺伝子数 : 150 - 標的パスウェイ数 : 225
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04313166 (ClinicalTrials.gov) | March 19, 2020 | 15/3/2020 | Treatment Continuation Study for Patients With ALS/MND Who Completed Study CMD-2019-001 | A Treatment Continuation Study for Patients With Amyotrophic Lateral Sclerosis/Motor Neuron Disease Who Have Successfully Complete Study CMD-2019-001 | Amyotrophic Lateral Sclerosis | Drug: Cu(II)ATSM | Collaborative Medicinal Development Pty Limited | NULL | Completed | 18 Years | 75 Years | All | 55 | Phase 2 | Australia |
| 2 | NCT04082832 (ClinicalTrials.gov) | September 30, 2019 | 2/9/2019 | CuATSM Compared With Placebo for Treatment of ALS/MND | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Cu(II)ATSM in Patients With Amyotrophic Lateral Sclerosis/Motor Neuron Disease | Amyotrophic Lateral Sclerosis | Drug: Cu(II)ATSM;Drug: Placebos | Collaborative Medicinal Development Pty Limited | NULL | Recruiting | 18 Years | 75 Years | All | 80 | Phase 2/Phase 3 | Australia |
| 3 | NCT03136809 (ClinicalTrials.gov) | January 18, 2018 | 28/4/2017 | ALS Treatment Extension Study | A Treatment Continuation Study for Patients With Amyotrophic Lateral Sclerosis/Motor Neuron Disease Who Have Successfully Completed Study CMD-2016-001 | Amyotrophic Lateral Sclerosis | Drug: Cu(II)ATSM | Collaborative Medicinal Development Pty Limited | NULL | Active, not recruiting | 18 Years | 75 Years | All | 28 | Phase 1/Phase 2 | Australia |
| 4 | NCT02870634 (ClinicalTrials.gov) | November 16, 2016 | 10/8/2016 | Phase 1 Dose Escalation and PK Study of Cu(II)ATSM in ALS/MND | A Phase 1 Single and Multiple Dose Escalation and Pharmacokinetic Study of Cu(II)ATSM Administered Orally to Patients With Amyotrophic Lateral Sclerosis/Motor Neuron Disease | Amyotrophic Lateral Sclerosis;Motor Neuron Disease | Drug: Cu(II)ATSM | Collaborative Medicinal Development Pty Limited | NULL | Completed | 18 Years | 75 Years | All | 50 | Phase 1 | Australia |